Sona Nanotech Inc. (SNANF)
OTCQB OTCQB Primary 
Sona Nanotech on a mission to make cancer treatment more effective with fewer side effects
Cancer is an oftentimes fatal condition that has touched most people's lives directly or indirectly. And while there are treatments available, depending on the type of cancer in question and how advanced it is, much of the time they do not work.
Sona Nanotech hits milestone in human trial readiness - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about a major regulatory milestone achieved by the company's golden nanorod therapy platform. The company announced that its therapy has successfully passed a key safety study, a required step before proceeding to human clinical trials.
Sona Nanotech advances cancer therapy program with positive preclinical study results
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced positive results from a preclinical safety study evaluating the toxicity of its proprietary gold nanorods, fulfilling a prerequisite required by the US Food and Drug Administration (FDA) for advancing to full human clinical trials. The study assessed the safety, tolerability, and tissue distribution of Sona's gold nanorods in three groups of twenty rats, each administered different dosage levels intravenously.
Sona Nanotech completes endotoxin testing ahead of human study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said it has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods, marking a key step ahead of the company's first-in-human early feasibility study. The results showed endotoxin levels below detection limits, with no interference observed in the assay, the company said.
Sona Nanotech chief medical officer talks latest targeted hyperthermia therapy findings - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) chief medical officer Dr Carman Giacomantonio talked with Proactive about the company's latest findings related to its targeted hyperthermia therapy (THT), which he described as showing “very enabling immunogenic” effects in recent experiments. The THT platform works by delivering controlled heat to the core of a tumour, triggering a natural cell death response and activating the body's immune system.
Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025
From potential changes in government healthcare policies to persistent inflationary pressures and evolving investment strategies, the US healthcare sector is facing a convergence of economic, regulatory, and political forces that could reshape the industry's trajectory for years to come. As the industry emerges from the lingering effects of the COVID-19 pandemic, healthcare companies must adapt to new cost structures, shifting reimbursement models, and an increasingly competitive landscape.
Sona Nanotech confirms THT's potential to enhance immunotherapy efficacy in preclinical study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that a follow-up preclinical study has confirmed the efficacy of its Targeted Hyperthermia Therapy (THT) in immunotherapy-resistant cancer. The company's THT utilizes Sona's patented, biocompatible gold nanorods (GNRs) to target specific solid tumors, reducing their size and stimulating the immune system.
Sona Nanotech's gold nanorod study hits peer-reviewed journal - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) earlier this week announced the publication of its preclinical cancer therapy study in Frontiers in Immunology. The company explained that its patented gold nanorod technology is at the center of Targeted Hyperthermia Therapy (THT), an innovative approach that destroys tumors using laser-induced heat.
Sona Nanotech's bold bet on cancer therapy: gold nanorods and the fight against “cold tumors”
For decades, cancer researchers have grappled with a stubborn challenge: the body's immune system often fails to recognize and attack tumors. While immunotherapies like Merck's Keytruda have revolutionized treatment, they still leave many patients behind.
Sona Nanotech: Peer-reviewed article underlines the potential of unique cancer therapy
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has taken a significant step forward with its experimental cancer treatment, Targeted Hyperthermia Therapy (THT). The results of its preclinical studies on breast cancer and melanoma have been published in Frontiers in Immunology, a leading peer-reviewed journal.
